Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
Overview
In Cathie Wood's Ark Genomic Revolution ETF (NYSEMKT: ARKG), as of July 10, the three top holdings are Tempus AI, 10x Genomics, and Twist Bioscience. But digging past the top 10 holdings, there's a $1.8 billion biotech company with a growing drug pipeline that's also landed big-name healthcare partnerships.
That company is Recursion Pharmaceuticals (NASDAQ: RXRX), and the Ark Genomic Revolution ETF currently owns over $50 million worth of its stock.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.